Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy

Ning Xu,Benjamin Tse,Lu Yang,Michelle Haber,Kenneth Micklethwaite,Alla Dolnikov,Tiffany CY Tang

DOI: https://doi.org/10.2147/ITT.S296161

2022-05-25

ImmunoTargets and Therapy

Abstract:Ning Xu, 1, 2 Benjamin Tse, 1, 2 Lu Yang, 1, 2 Tiffany CY Tang, 1, 2 Michelle Haber, 1, 2 Kenneth Micklethwaite, 3– 6 Alla Dolnikov 1, 2 1 Children's Cancer Institute, University of New South Wales, Sydney, NSW, Australia; 2 School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia; 3 Blood Transplant and Cell Therapies Program, Department of Hematology, Westmead Hospital, Sydney, NSW, Australia; 4 Sydney Cellular Therapies Laboratory, NSW Health Pathology, Sydney, NSW, Australia; 5 Westmead Institute for Medical Research, Sydney, NSW, Australia; 6 Sydney Medical School, The University of Sydney, Sydney, NSW, Australia Correspondence: Alla Dolnikov Children's Cancer Institute, University of New South Wales, PO Box 81, Randwick, NSW, 2031, Australia Tel +61 449 904 174 Email Purpose: Despite the success of chimeric antigen receptor (CAR) T cells in clinical studies, a significant proportion of responding patients eventually relapsed, with the latter correlating with low CAR T cell expansion and persistence. Methods and Results: Using patient-derived xenograft (PDX) mouse models of CD19 + B cell acute lymphoblastic leukemia (B-ALL), we show that priming leukemia-bearing mice with 5-azacytidine (AZA) enhances CAR T cell therapy. AZA given 1 day prior to CAR T cell infusion delayed leukemia growth and promoted CAR T cell expansion and effector function. Priming leukemia cells with AZA increased CAR T cell/target cell conjugation and target cell killing, promoted CAR T cell divisions and expanded IFNγ + effector T cells in co-cultures with CD19 + leukemia Nalm-6 and Raji cells. Transcriptome analysis revealed activation of diverse immune pathways in leukemia cells isolated from mice treated with AZA. We propose that epigenetic priming with AZA induces transcriptional changes that sensitize tumor cells to subsequent CAR T cell treatment. Among the candidate genes up-regulated by AZA is TNFSF4 which encodes OX40L, one of the strongest T cell co-stimulatory ligands. OX40L binds OX40, the TNF receptor superfamily member highly specific for activated T cells. TNFSF4 is heterogeneously expressed in a panel of pediatric PDXs, and high TNFSF4 expression correlated with increased CAR T cell numbers identified in co-cultures with individual PDXs. High OX40L expression in Nalm-6 cells increased their susceptibility to CAR T cell killing while OX40L blockade reduced leukemia cell killing. Conclusion: We propose that treatment with AZA activates OX40L/OX40 co-stimulatory signaling in CAR T cells. Our data suggest that the clinical use of AZA before CAR T cells could be considered. Keywords: CAR T cells, leukemia, AZA, patient-derived xenografts, gene expression Adoptive therapy with patient T cells modified to express chimeric antigen receptors (CAR) has demonstrated great success in clinical trials. 1–3 CAR redirects T cells to recognize and eliminate tumor cells. 4 Three CD19-targeting CAR T cell products have been approved for the treatment of relapsed or refractory large-cell lymphomas and B cell acute lymphoblastic leukemia (B-ALL) in children and young adults (Gilead's axicabtagene ciloleucel and Novartis's tisagenlecleucel) and mantle cell lymphoma (MCL) in adults (Gilead's brexucabtagene autoleucel). High response rates ranging from 70% to 94% have been achieved using both CAR T cell products. However, a significant proportion of responding patients eventually relapsed with either CD19 – or CD19 + disease. 5 Short duration of remission in patients treated with CAR T cells correlated with limited CAR T cell expansion and lack of persistence. 6 The in vivo expansion and persistence of adoptively transferred CAR T cells are potentially modulated by premature exhaustion of T cells in patients heavily pre-treated with chemotherapy, T cell exhaustion induced by extensive CAR T cell expansion during manufacture, and the immune-suppressive tumor microenvironment (TME). 7–9 DNA methyltransferase (DNMT) inhibitors such as 5-azacytidine (azacitidine, AZA) and 5-aza-2ʹ-deoxycytidine (decitabine, DEC) have been shown to promote immune responses in multiple tumor types. 10 DNMT inhibitors up-regulate the expression of tumor-associated antigens (TAA), co-stimulatory ligands and human leukocyte antigen (HLA) molecules important for tumor antigen presentation and activate type I interferon (IFN) signaling in some cancers through the viral defense pathway. 11–13 The combination of DNMT inhibitor -Abstract Truncated-